ASCO

Weekly Update of New Journal of Clinical Oncology Online Articles

EDITORIALS

For Head and Neck Cancer, It Is Still Cisplatin, But How Much, How Often, and How Tolerable? New Randomized Phase III Data For the Adjuvant Setting
Neil Hayes et al.

ORIGINAL REPORTS

Breast Cancer

Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial
Vliek et al.

Cancer Prevention and Control

Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors
Timmerman et al.

Gastrointestinal Cancer

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Shen et al.

Genitourinary Cancer

Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216)
Agarwal et al.

Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
Atkins et al.

Supportive Care and Quality of Life

Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy
Meglio et al.

Thoracic Oncology

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer
Herbst et al.

ART OF ONCOLOGY

Questions for the Oncologist
Meisenberg et al.

CORRESPONDENCE

Artificial Intelligence Risk Model (Mirai) Delivers Robust Generalization and Outperforms Tyrer-Cuzick Guidelines in Breast Cancer Screening
Jin et al.

Reply to M. Eriksson et al and Z. Jin et al
Yala et al.

Risk Assessment in Population-Based Breast Cancer Screening
Eriksson et al.

Impact of Novel Hormonal Therapy on Cognitive Function: Essential to Measure, Difficult to Present
Marandino et al.

Reply to L. Marandino et al
Dzimitrowicz et al.

Reply to L. Marandino et al
Stockler et al.

The Latest From ASCO

JCO After Hours: A Discussion With Veena Shankaran and Scott Ramsey
Shannon Westin, Veena Shankaran, and Scott Ramsey discuss their article about financial toxicity and the impact of cancer diagnosis on patients' credit standing. Listen now.

Sign up for ASCO Daily News Emails
Don’t miss the latest oncology news and commentary. Opt-in now.

Questions for the Oncologist by Barry Meisenberg
In this JCO episode of Cancer Stories, Barry Meisenberg shares his poem on the struggles to answer a patient’s “Why me?” question. Listen to his poem and interview.

The Use of Biosimilars in Oncology
Host Dr. John Sweetenham and Dr. Zeina Nahleh discuss the new ASCO Expert Panel report on the use of biosimilars in oncology, and their potential as an affordable, effective alternative for cancer care. Listen now.

Manage your preferences for
ASCO Journals email alerts

American Society of Clinical Oncology
2318 Mill Road, Suite 800
Alexandria, VA 22314
USA
571-483-1300
ASCO.org • ascopubs.org

Unsubscribe